News

Immutep Limited has signed a Clinical Trial Collaboration and Supply Agreement with Merck Group and Pfizer for a new Phase I clinical study in urothelial cancer patients called INSIGHT-005.

Posted: 29 November Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immuno therapies for cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany…

Levelling up advanced manufacturing at RMIT

Posted: 29 November RMIT’s Advanced Manufacturing Precinct (AMP) is expanding to include 3 cutting-edge facilities that will deliver 21st century manufacturing. The new, expanded precinct will remain based at the City Campus site and accommodate the original AMP now known as…

U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

Posted: 24 November Global biotechnology leader CSL announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the…

2022 BioMelbourne Network Annual General Meeting wrap

Posted: 18 November 2022 The 2022 BioMelbourne Network Annual General Meeting and Networking Event was held on Thursday 17 November in person and online. Honorary Life Membership awards BioMelbourne Network bestows Honorary Life Membership awards to Members whose…

4DMedical Debuts “XV Scanner,” Most Advanced Lung Scanning Technology in Decades At RSNA

Posted: 18 November 4DMedical will unveil the “XV Scanner,” a breakthrough lung scanning device that integrates fluoroscopy with advanced analytics software at the 2022 annual meeting of the Radiological Society of North America (RSNA) in Chicago. The XV…

Phase 2 trial of ChulaCov19 BNA159 mRNA Vaccine to start in Australia

Posted: 18 November ChulaCov19 BNA159 is a COVID-19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet • ChulaCov19 mRNA vaccine was found safe and immunogenic for primary immunization in clinical trials in Thailand. • The Australian…

ARCS Signature Program

Posted: 16 November Closes: 13 January 2023 The ARCS Signature Program is designed for senior executives and emerging leaders who are working in the med tech, biotech and pharmaceutical sectors. This includes those who are part of a…

Backing business events to support jobs and innovation

Posted: 15 November The City of Melbourne has doubled its funding to support conferences, workshops and other business events – bringing more people together to drive innovation and boost the economy. An augmented reality festival, sustainable tech pitch…

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC

Posted: 11 November Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced compelling new clinical data from the TACTI-002 all-comer PD-L1 Phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha…

Researchers make strides in the fight against COVID-19

Posted: 9 November New research from the Peter Doherty Institute of Infection and Immunity (Doherty Institute), The University of Melbourne and WEHI has unlocked key information in our understanding of molecular immune responses to COVID-19. Following COVID-19 infection,…

Virus discovery could help fight cancer

Posted: 9 November In a world first, La Trobe University researchers have discovered a virus that attacks a prominent disease-causing bacterium – a “ringleader” that recruits harmful bacteria to cause periodontitis, and potentially helps cancer grow and spread.…

Home

News & opinion

Member Directory

Events